Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.84 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.66 |
| ▸ | CSF1R | P07333 | 2/20 | 0.66 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.66 |
| ▸ | FLT3 | P36888 | 1/20 | 0.66 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.66 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13399869 | 0.88 | AURKA (0.70) | AURKAAURKBCSF1RNTRK1FLT3 | |
| SCHEMBL13399867 | 0.88 | AURKA (0.70) | AURKAAURKBCSF1RNTRK1FLT3 | |
| SCHEMBL13399863 | 0.87 | AURKA (0.81) | AURKAAURKBCSF1RNTRK1FLT3 | |
| SCHEMBL13399795 | 0.87 | AURKA (1.00) | AURKAAURKBCSF1RNTRK1FLT3 | |
| SCHEMBL13399732 | 0.87 | AURKA (0.82) | AURKAAURKBNTRK1KDREGFR | |
| SCHEMBL13399808 | 0.84 | AURKA (0.80) | AURKAAURKBCSF1RNTRK1FLT3 | |
| SCHEMBL13399784 | 0.84 | AURKA (0.84) | AURKAAURKBCSF1RNTRK1FLT3 | |
| SCHEMBL13399874 | 0.84 | AURKA (0.69) | AURKAAURKBCSF1RNTRK1FLT3 | |
| SCHEMBL13399865 | 0.83 | AURKA (0.72) | AURKAAURKBCSF1RNTRK1FLT3 | |
| SCHEMBL13399987 | 0.83 | AURKA (0.83) | AURKAAURKBCSF1RNTRK1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006252-B2 | Fused multicyclic compounds as protein kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-04-14 | — | — | US | disclosed |
| US-9006252-B2 | Fused multicyclic compounds as protein kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-04-14 | — | — | US | disclosed |
| EP-2331530-B1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (CN) | 2013-08-21 | — | — | EP | disclosed |
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | US | disclosed |
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885CSF1R 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.